Penn Pharma appoints two directors

Company: PCI Pharma Services

To be based at South Wales facility

Richard Yarwood has joined UK-based pharmaceutical services provider Penn Pharma. He has more than 33 years of experience in the pharmaceutical industry and will now manage the South Wales headquartered business as its expands and strengthens its services and international presence.

Yarwood has held senior positions including group president of sterile technologies at Catalent Pharma Solutions and president for Europe and Asia Pacific at Catalent.

A pharmacy graduate from Nottingham University, Yarwood gained a PhD from Manchester University and an MBA from Warwick University before pursuing a career in the pharmaceutical industry.

Penn has also appointed David Cooper as operations director. Previously general manager of oral technologies at Zydis, Cooper also has extensive experience in global manufacturing, gained from Mylan Pharmaceuticals, formerly Merck Generics.

Mark Molyneux, chairman of Penn Pharmaceutical Services, said: ‘Both Richard and David will be valuable additions to our board of directors, and their appointments mark another important step as the company rolls out a £12m expansion programme over the next five years.’

Penn Pharma was established more than 30 years ago and since then has provided integrated drug development, clinical trial supply and manufacturing services to the healthcare industry.



You may also like

Manufacturing

At BIO Show in Boston, PCI Pharma Services to provide updates on new manufacturing facility

For leading CDMO, qualification activities for plant’s state-of-the-art sterile fill-finish and lyophilisation line are underway, with GMP production commencing summer 2025
Manufacturing

Targeted protein degraders: transforming oral therapeutics

Targeted protein degraders (TPDs) are redefining modern drug discovery and development, offering a revolutionary approach to treating diseases that were once considered to be untreatable
Manufacturing

PCI Pharma Services acquires Ajinomoto Althea, makes ground on US and European expansion

PCI's acquisition of US-based sterile fill-finish CDMO Ajinomoto Althea is part of the company's overarching strategy to expand its drug delivery services within the US and Europe
Manufacturing

PCI Pharma Serives acquires US-based sterile fill-finish CDMO, Ajinomoto Althea

This acquisition will add antibody-drug conjugate (ADC) manufacturing and US-based sterile fill-finish production capabilities to PCI's portfolio
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

The rise of targeted modalities in pharmaceutical development

Targeted modalities represent a significant evolution in drug development, reports Anshul Gupte, Vice President of Pharmaceutical Development at PCI Pharma Services. They distinguish themselves from traditional small molecules and biologics by focusing on precise mechanisms of action
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

CDMO insights: development and manufacture of a highly potent OSD product

In today’s pharmaceutical landscape, contract development and manufacturing organisations (CDMOs) are ubiquitous. Prior to the CDMO boom in the 1990s, however, this wasn’t the case
Manufacturing

PCI Pharma Services invests $365m into its advanced injectable packaging capabilities

The company has expanded its final assembly and packaging capabilities for advanced injectable solutions in both Europe and the US
Subscribe now